Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences 3D-Models for Drug Testing: Organoids & Tissue Chips 2022

Jeffrey Borenstein's Biography



Jeffrey Borenstein, Group Leader, Synthetic Biology; Director, Biomedical Engineering Center, Draper

Jeffrey T. Borenstein, PhD, is Group Leader for Synthetic Biology and Bio Instrumentation and Director, Biomedical Engineering Center at Draper in Cambridge, Massachusetts, where he leads programs in organ and disease models for drug discovery and safety testing, immuno-oncology platforms, organ assist devices and drug delivery systems. He has a Ph.D. in Physics and over twenty-five years of experience in the application of microsystems and microfabrication technologies toward medicine. Dr. Borenstein holds over 60 issued patents and 100 peer-reviewed journal articles and is a member of the National Academy of Inventors.

Jeffrey Borenstein Image

Using Organs-on-Chips for Screening Therapeutics for Pandemic Respiratory Infections

Wednesday, 14 September 2022 at 09:00

Add to Calendar ▼2022-09-14 09:00:002022-09-14 10:00:00Europe/LondonUsing Organs-on-Chips for Screening Therapeutics for Pandemic Respiratory Infections3D-Models for Drug Testing: Organoids and Tissue Chips 2022 in SeattleSeattleSELECTBIOenquiries@selectbiosciences.com

One of the most powerful applications of organs-on-chips is as a platform for generating human-relevant data in screening therapeutic candidates across various disease models.  Here we present recent therapeutic screening results obtained using the high throughput human primary tissue culture platform PREDICT96-ALI (Air Liquid Interface) across pandemic respiratory infections including Influenza A Virus (IAV) and the coronaviruses hCoV-NL63, hCoV-OC43 and SARS-CoV-2.  These platforms, seeded with human primary tracheobronchial epithelial cells obtained from commercial sources as well as directly from bronchoscopies performed on living donors, enable rapid screening across a range of conditions including infection levels, cell source, candidate compound and therapeutic dose.  In the case of SARS-CoV-2, this represents a first demonstration of successful therapeutic screening in a high containment BSL-3 environment.  Results from the airway platform correlate closely with clinical data, demonstrating a compelling opportunity for an organ-on-chip model to serve a critical role in evaluating potential candidates capable of efficaciously treating severe respiratory infections.


Add to Calendar ▼2022-09-13 00:00:002022-09-14 00:00:00Europe/London3D-Models for Drug Testing: Organoids and Tissue Chips 20223D-Models for Drug Testing: Organoids and Tissue Chips 2022 in SeattleSeattleSELECTBIOenquiries@selectbiosciences.com